XiaoMi-AI文件搜索系统
World File Search Systemachieved
血浆宏基因组下一代测序的应用可改善中性粒细胞减少或造血干细胞移植的血液学患者的预后
Results: In 153 plasma samples, mNGS yielded a higher positivity rate than CMT (total: 88.24% vs. 40.52%, P<0.001; bacteria: 35.95% vs. 21.57%, P < 0.01; virus: 69.93% vs. 21.57%, P<0.001; fungi: 20.26% vs. 7.84%, p <0.01）。中性粒细胞减少症组细菌和真菌的阳性率高于非中性粒细胞减少组（细菌：48.61％vs. 24.69％，p <0.01; Fungi：27.78％vs. 13.58％，p <0.05）。MNG在造血干细胞移植（HSCT）的患者组中显示出更大的优势。HSCT组的3天和7天的效率均高于非HSCT组的3天和7天（3天：82.22％：82.22％，58.65％，p <0.01; 7天：88.89％：88.89％vs. 67.31％，67.31％，P <0.01），而HS中的HS在HS中均低于HS的6％。 38.89％，p <0.000）。The neutropenia group achieved similar ef fi cacy and mortality rates to the non-neutropenia group (7-day ef fi ciency rate: 76.39% vs. 71.43%, P > 0.05; mortality rate: 29.17% vs. 29.63%, P > 0.05) with more aggressive antibiotic adjustments (45.83% vs. 22.22%, P < 0.01）。
lineZolid负载的纳米颗粒用于局部糖尿病脚治疗：配方，体外和离体表征
这项研究的目的是制定含纳米颗粒的局部凝胶，用于糖尿病足溃疡（DFU）。在这方面，使用自发乳化技术制备纳米颗粒制剂。lineZolid（LZD）负载的纳米颗粒配方表现出较低的平均颗粒尺寸（PS）为195.27±5.42 nm，低散射指数（PI）为0.214±0.019，高Zeta势率（ZP）高Zeta电位（ZP），为20.57±0.35 mV和高毒药效率（99.09）。为了提高局部停留时间，使用甲基TM K4M（HPMC）和Carbopol®974P NF将LZD负载的纳米颗粒分散在凝胶配方中。配制的凝胶表现出有利的特性，包括适当的pH值，适当的机械性能以及理想的粘度和局部应用的可传播性。所有配方均显示了指定频率值的假塑性流和典型的凝胶型机械光谱。Moreover, the developed formulation achieved sustained drug release as intended for these systems.During ex vivo drug diffusion studies, 0.007±0.004% of LZD was found in receptor phase, indicating a local effect.The optimum formulation was stable for six months.最初的发现表明，配制的含有LZD的纳米颗粒的局部凝胶具有有效的DFU管理药物输送系统。However, further comprehensive investigations are required to substantiate this hypothesis.
Genetics and beyond
Abstract: Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker- guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.
对内存系统实际处理的机器学习培训的实验评估
摘要 - 大约三分之一的2型糖尿病患者（T2D）升级为基础胰岛素注射。基底胰岛素剂量被滴定以实现一个不高血糖风险的严重血糖靶标。在护理标准（SOC）中，滴定基于间歇性禁食血糖（FBG）的调查。缺乏依从性和FBG测量中的日常变异性是现有胰岛素滴定程序的限制因素。我们提出了一种自适应退化的地平线控制策略，其中识别出葡萄糖 - 胰岛素空腹模型并用于预测最佳的基础胰岛素剂量。使用新的UVA虚拟实验室（UVLAB）评估了该算法在Silico实验中评估，并与一组与临床数据相匹配的T2D头像（NCT01336023）。与SOC相比，我们表明，这种控制策略可以更快地实现相同的葡萄糖靶标（在第8周时）和更安全（低血糖保护和对缺失FBG测量的鲁棒性）。Specifically, when insulin is titrated daily, a time-in-range (TIR, 70–180 mg/dL) of 71.4 ± 20.0% can be achieved at week 8 and maintained at week 52 (72.6 ± 19.6%) without an increased hypoglycemia risk as measured by time under 70 mg/dL (TBR, week 8: 1.3 ± 1.9% and week 52: 1.2与SOC相比（第8：59.3±28.0％和周的TIR相比，±1.9％）。这种方法可以潜在地减少治疗惯量和处方复杂性，从而改善使用基底胰岛素注射的T2D血糖结果。
RL-VLM-F：从视觉语言基础模型反馈
在图像1还是图像2中可以更好地实现目标？如果在图像1中更好地实现了目标，请回复0行，如果在图像2中更好地实现了目标。回复-1如果文本不确定或没有区别。
Advanced Certificate in Mechanical Engineering
Assessment Technique (s) including weighting (s) The Advanced Craft Certificate grade is based on a weighted average of all unit result grades. Assessment approach varies from one unit to another. During every unit of study there is a minimum number of continuous assessments which the learner must undertake. This could be in the form of small tests and assignments and research. For the final unit assessments, in most cases a learner will have to sit for both a theory paper which can be multiple choice, structured or a mixture and a practical for skills demonstration. Work based experience (WBE) is a compulsory unit and is assessed by the supervisor in the work place for full-time learners and through compilation of a portfolio and assessed against the performance criteria for the different elements in the WBE unit for learner on part-time. To attain the required standard, a minimum of a pass grade must be achieved in all assessments prescribed . Pass mark for every unit on the programme is 55%. As per SIT Assessment Policy, the final mark for a unit is made up of 40% of all continuous assessments plus 60% from the results of the final unit assessment (s) and the following grades and corresponding marks are used Not yet Competent- NYC-0 - 54% Pass - P - 55%-69% Credit or Merit - M or C - 70% - 84% Distinction - D - 85%+ -
Scalable preparation of asymmetrical bilayer sulfide/halide electrolyte membranes for all-solid-state batteries with high voltage
抽象的全稳态电池（ASSB）被认为是提高电池安全性和能量密度的最有希望的候选者。硫化物电解质具有狭窄的电化学窗口，该窗口阻碍了其应用与高压阴极。具有高压耐力的卤化物电解质可以帮助解决此问题。在此，采用喷涂和污染方法的组合用作处理自由的LI 6 PS 5 Cl（LPSCL）不对称的电解质膜（19.23Ωcm2，75μm），用10μmLi3包含6（Licl）层装饰。LICL-LPSCL不对称的电解质膜增强了高压稳定性，使LINI 0.83 CO 0.83 CO 0.11 Mn 0.06 O 2（NCM811）和LI 1.2 Ni 0.13 CO 0.13 CO 0.13 CO 0.13 Mn 0.54 0.54 O 2（LRMO）Cathodes。NCM811 | LICL-LPSCL | NSI ASSB的初始库仑效率（ICE）为85.13％，在200个周期后的容量保留率为77.16％。Compared with the LPSCl membrane, the LICl-LPSCl membrane displayed high stability with the LRMO cathode as the charging cut-off voltage increased to 4.7 V, which improved the initial charge capacity from 143 to 270 mAh g −1 and achieved stable cycling of 160 mAh g −1 at 0.5 C. Additionally, we attempted continuous LICl-LPSCl membrane production and utilized the product to fabricate a基于LRMO的小袋型ASSB。LICL-LPSCL电解质膜的制造证明了其在Assbs中的可控和行业适应应用的潜力。
2023 - OR复制前向排除列表
•基准年范围3，类别[1-17]涵盖的排放（公制CO2E）（第12-28列）（第12-28列）•基准年范围3，类别[1-17]覆盖的目标涵盖的排放量为SCOPE 3中基准年总发射的百分比，类别3，类别[1-17]（报告1-17]（TARGITS CO2E）（Metric Tons CO2E）（Metric Tons COPOPE） CO2E（第55列），范围2在报告年度覆盖的报告年度（公制CO2E）（第56列）（第56列），范围3，类别[1-17]的报告年份的排放量为目标年度涵盖的报告年度（公制CO2E）（公制吨CO2E）（57-73列）（第57-73列）•报告年度范围范围范围范围3范围范围范围范围范围范围范围范围范围范围范围3（IMISS target）（EMISS by co2e）（Emiss by co2e）（METRIC TIM）（METRIC THING）（METRIC TOM）•METRIC TOMISRIC TABIRIC TOM 2E）所有选定的示波器（公制CO2E）（第75列）•此目标是否涵盖任何与土地相关的排放？(column 76) • % of target achieved relative to base year [auto-calculated] (column 77) • Target status in reporting year (column 78) • Please explain target coverage and identify any exclusions (column 79) • Plan for achieving target, and progress made to the end of the reporting year (column 80) • List the emissions reduction initiatives which contributed most to achieving this target (column 81)
Batumi绿色经济倡议（BIG-E）
国家：中亚环境中心（CAREC）标题：对实现UNECE重点领域的跨界公约的支持6：促进行动的绿色和公平贸易描述：支持CA国家报告和发展UNECE Credions Action Action Action Action Action Action Action Action time-Timegrame/Milestones的综合方法，适用于：2017-2022年的构建类型的构建类型和驾驶类型。经济部门：城市；各个部门，包括：农业，林业，捕鱼，能源，采矿，运输，水，废物，废物，旅游和住房，建筑物和建筑参考文献和资源，可恰当：计划的项目预算，将在计划中的项目预算进行，以密切的合作和支持，对开发计划署，UNEP，CAREC，CAREC，CAREC，CAREC，CAREC，CAREC，EU和其他感兴趣的Partners的工具以及该工具的工具以及CA的工具将在此过程中及时设计，该工具将在此过程中及其启动的工具，该工具的工具是设计，该工具是在设计中的工具，该仪器是在设计中，该工具是在设计中，该工具是在设计中，该工具是在设计的，该工具是在设计中，该工具是在设计中，该工具是在设计中的。 monitoring and reporting on achieved results SDGs target(s) that the action may contribute to implement : (SDG 3, 6, 14, 15) Implementation of Environmental Performance Review (EPR) Recommendations, as appropriate : N/A Objectively verifiable indicators, as appropriate : Capacity building trainings (5 CA countries) Partners : National partners, including State Statistics Committees, Ministries of economy, Ministries of the Environment protection Contact point : Saltanat Zhakenova Email: szhakenova@carececo.org
Casgevy™ (exagamglogene autotemcel)
Casgevy (exagamglogene autotemcel) is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). Casgevy was evaluated in an ongoing single-arm, multicenter, phase 1/2/3 trial with patients who had a history of at least 2 protocol-defined severe VOC events during each of the 2 years prior to screening. Of the 63 patients enrolled in the trial, 44 patients went on to receive Casgevy to form the full analysis set (FAS). Of the 44 patients from the FAS, 31 had adequate follow-up to allow evaluation of the primary efficacy endpoint and formed the primary efficacy set (PES). The primary efficacy outcome was the proportion of VF12 responders, defined as patients who did not experience any protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after treatment with Casgevy. The VF12 response rate was 29/31 (93.5%, 98% one-sided CI: 77.9%, 100.0%). The proportion of patients who did not require hospitalization due to severe VOCs for at least 12 consecutive months within the 24-month evaluation period (HF12) was also assessed. One patient was not evaluable for HF12 response; the remaining 30 patients achieved the endpoint of HF12 (100% [98% one-sided CI: 87.8%, 100.0%]). The most common grade 3 or 4 adverse reactions with an incidence ≥25% were mucositis, febrile neutropenia, and decreased appetite. The most common grade 3 or 4 laboratory abnormalities (≥ 50%) were neutropenia, thrombocytopenia, leukopenia, anemia, and lymphopenia.